| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
44,696,000 |
| Market
Cap: |
11.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.156 - $0.62 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for serious cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan. Co.'s programs include: TNX-103 and TNX-102 (levosimendan), a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and TNX-201(imatinib), a tyrosine kinase inhibitor, which changed the treatment of chronic myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Blanck Ronald R |
|
• • – |
2017-12-18 |
4 |
B |
$0.45 |
$5,887 |
D/D |
12,950 |
20,099 |
0.01 |
- |
|
| Blanck Ronald R |
|
• • – |
2017-11-14 |
4 |
S |
$0.39 |
$5,051 |
D/D |
(12,950) |
7,149 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2017-07-31 |
4 |
|
$0.65 |
$35 |
D/D |
54 |
68,146 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2017-04-15 |
4 |
|
$0.54 |
$30 |
D/D |
56 |
68,200 |
|
- |
|
| Kelley John P |
Chief Executive Officer |
• • – |
2017-03-15 |
4 |
D |
$0.68 |
$65,959 |
D/D |
(96,999) |
1,282,932 |
|
- |
|
| Kelley John P |
Chief Executive Officer |
• • – |
2017-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
213,420 |
1,379,931 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2016-12-19 |
4 |
|
$2.07 |
$101 |
D/D |
49 |
68,256 |
|
- |
|
| Proehl Gerald T |
Director |
• • – |
2016-11-23 |
4 |
B |
$1.76 |
$25,430 |
D/D |
14,449 |
29,882 |
2.39 |
- |
|
| Proehl Gerald T |
Director |
• • – |
2016-11-22 |
4 |
B |
$1.59 |
$24,538 |
D/D |
15,433 |
15,433 |
2.39 |
- |
|
| Mitchum James P. |
Director |
– • – |
2016-11-21 |
4 |
|
$1.51 |
$10,570 |
D/D |
7,000 |
26,000 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2016-09-30 |
4 |
D |
$2.32 |
$114 |
D/D |
(49) |
68,305 |
|
- |
|
| Rallis Chris A |
Director |
– • – |
2016-08-19 |
4 |
|
$2.50 |
$25,000 |
D/D |
10,000 |
14,490 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2016-06-01 |
4 |
D |
$2.72 |
$150 |
D/D |
(55) |
68,354 |
|
- |
|
| Blanck Ronald R |
Director |
– • – |
2016-05-23 |
4 |
|
$2.62 |
$9,170 |
D/D |
3,500 |
20,099 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2016-05-01 |
4 |
A |
$2.72 |
$1,170 |
D/D |
430 |
68,409 |
|
- |
|
| Mitchum James P. |
Director |
• • – |
2016-02-03 |
4 |
B |
$2.65 |
$36,835 |
I/I |
13,900 |
19,000 |
2.66 |
- |
|
| Blanck Ronald R |
Director |
– • – |
2016-02-02 |
4 |
|
$2.69 |
$4,842 |
D/D |
1,800 |
16,599 |
|
- |
|
| Mitchum James P. |
Director |
• • – |
2016-02-02 |
4 |
B |
$2.68 |
$13,668 |
I/I |
5,100 |
5,100 |
2.58 |
- |
|
| Jebsen Michael B |
CFO |
• – – |
2016-01-29 |
4 |
|
$2.65 |
$148 |
D/D |
56 |
67,979 |
|
- |
|
| Blanck Ronald R |
Director |
– • – |
2015-11-19 |
4/A |
B |
$3.26 |
$15,322 |
D/D |
4,700 |
12,899 |
2.39 |
- |
|
| Blanck Ronald R |
Director |
– • – |
2015-11-19 |
4 |
B |
$3.20 |
$6,080 |
D/D |
1,900 |
14,799 |
2.39 |
- |
|
| Jebsen Michael B |
CFO |
• – – |
2015-10-31 |
4 |
|
$3.19 |
$156 |
D/D |
49 |
68,035 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2015-07-31 |
4 |
|
$3.68 |
$180 |
D/D |
49 |
68,084 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2015-05-15 |
4 |
|
$3.42 |
$1,471 |
D/D |
430 |
68,133 |
|
- |
|
| Jebsen Michael B |
CFO |
• – – |
2015-05-15 |
4 |
|
$3.44 |
$189 |
D/D |
55 |
67,703 |
|
- |
|
172 Records found
|
|
Page 3 of 7 |
|
|
